-
Posted by
Two Blokes May 28, 2025 -
Filed in
Stock
-
13 views
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) said it is in active discussions over multiple large-scale commercial opportunities with pharmaceutical and diagnostics companies, as it continues to build momentum in the liquid biopsy market. The AIM-listed group, which develops blood tests to detect and monitor cancer by analysing circulating tumour cells (CTCs), said the timing of these potential deals remains uncertain, and tends to be 'binary in nature', but noted they could deliver growth beyond the modest increase expected for 2025.
